Treatment studies
tested Sleep efficiency, sleep latency, sleep structure (polysomnography), subjective sleep quality, subjective tiredness
result DSIP showed higher sleep efficiency and shorter sleep latency vs placebo, but effects were weak and partly attributable to incidental placebo group change; no improvement in subjective sleep quality; concluded not of major therapeutic benefit.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Treatment studies
tested Bispectral index (BIS), EEG parameters (delta rhythm, burst suppression, bilateral symmetry), heart rate variability (HRV)
result DSIP 25 nmol/kg paradoxically increased BIS (lighter anaesthesia), reduced delta rhythm and burst suppression, increased HR, decreased HRV, and altered bilateral EEG symmetry during isoflurane.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Treatment studies
tested night sleep quality (polysomnography), daytime alertness and mental performance
result DSIP substantially improved night sleep from first dose; effects maintained 1 posttreatment night. Sleep efficiency reached normal-control levels. Daytime alertness and performance increased significantly.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Treatment studies
tested Quality of life (SCAG scale), sleep, BP, ABI, pallesthesia, microalbuminuria, post-load glycemia, GH, insulin, cortisol, DHEAS
result SCAG scores improved (memory p=0.003, mood p=0.019, anxiety p=0.000); MAU↓ p=0.011; post-load glycemia↓ p=0.033; basal GH↓ p=0.034; reactive GH↓ p=0.005; DHEAS↑ (ns).
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Diagnostic & mechanistic studies
tested plasma DSIP levels (radioimmunoassay) and quiet/active sleep ratio (polysomnography)
result Healthy full-terms had higher DSIP (median 1885 pmol/l) vs preterms (1595, p<0.05) and high-apnea infants (1542, p<0.05); no difference vs SIDS siblings (1605).
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Diagnostic & mechanistic studies
tested plasma ACTH-like immunoreactivity, plasma cortisol, urinary cortisol, urinary monoamine metabolites
result Significant reduction of ACTH-LI in plasma for ≥3 hr after DSIP vs saline (control showed slightly elevated ACTH-LI). Plasma cortisol unaffected; no urinary differences.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Treatment studies
tested visual evoked potential (VEP) latent period, amplitude, and recovery time after macular photostress
result VEP restoration time reduced from 137.2±11.3 s to 95.1±6.8 s; decreased latent period and less pronounced VEP amplitude depression after photostress.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Treatment studies
tested polysomnographic sleep parameters: awakenings, NREM latency, total sleep time, stage 2 sleep, SWS, REM
result NREM sleep time and stage 2 increased under DSIP vs placebo (significant), but baseline differences pre-existed; no significant change in awakenings, waking time, SWS, or REM. Clinical significance deemed minimal.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Treatment studies
tested normalization of sleep patterns assessed in sleep laboratory during 1-week treatment and 1-week follow-up
result Middle-aged insomniacs normalized sleep by end of DSIP week, maintained at follow-up. Elderly (initial disturbance 2× more severe) normalized by end of follow-up. Whole sample showed normal sleep at study end; effects correlated with baseline severity.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Treatment studies
tested sleep quality, sleep structure normalization, daytime activity
result Single 25 nmol/kg injections improved sleep; repeated doses normalized sleep structure after 4 administrations; morning injections boosted daytime activity + night sleep; twice-daily dosing less effective.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Treatment studies
tested sleep normalization, daytime mood and performance
result 6/7 patients achieved sleep normalization for 3-7 months follow-up; daytime mood and performance also improved.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Treatment studies
tested polygraphic sleep recordings, psychophysiological tests, alertness/performance measures, psychological evaluation of ego functions
result Complete normalization of disturbed sleep after 4 consecutive injections; sleep latency ~1 h, duration up to 20 h; improved alertness and performance during waking; better stress tolerance and coping.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Treatment studies
tested total sleep time, sleep onset latency, stage 1 %, sleep efficiency, EEG/behavioral sedation
result Sleep increased 59% (median TST) within 130 min post-dose vs placebo; delayed night-sleep effects: shorter sleep onset, reduced stage 1%, improved sleep efficiency; no classic pharmacologic sedation on EEG.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Treatment studies
tested sleep duration, sleep quality, REM sleep, daytime sedation
result Longer sleep duration, higher quality with fewer interruptions, slightly more REM sleep; effects seen up to 6h of night sleep; slight arousing effect in first hour post-injection.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Diagnostic & mechanistic studies
tested Plasma AVP and ACTH concentrations under basal, osmotic (hypertonic NaCl), and orthostatic (20-min standing) conditions
result DSIP significantly decreased ACTH vs saline alone; had no effect on basal AVP or on AVP responses to hypertonic NaCl or orthostatic challenge. Timing (0 vs −60 min) did not alter results.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Diagnostic & mechanistic studies
tested Plasma ACTH and cortisol responses to CRH stimulation and meal-related midday surge
result DSIP 3–4 mg IV had no effect on ACTH or cortisol responses to CRH (1.0 or 0.5 µg/kg) vs placebo (n=5 each); 4 mg also did not alter meal-induced midday ACTH/cortisol surge (n=10).
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Diagnostic & mechanistic studies
tested Plasma concentrations of DSIP, P-DSIP, and other hormones/neurotransmitters measured every 30 min across two 24-h conditions
result DSIP and P-DSIP showed no or minimal changes between activity vs rest conditions. LH, TSH, heart rate, temperature increased with activity; cortisol/melatonin onset retarded.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Diagnostic & mechanistic studies
tested Serum GH and PRL levels, circadian rhythm of GH/PRL, GH/PRL responsiveness to arginine stimulation
result DSIP 25 µg/kg IV did not alter basal GH/PRL, their circadian rhythm, or arginine-stimulated GH/PRL response in 8 healthy women.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Diagnostic & mechanistic studies
tested plasma DSIP-LI levels at sleep initiation across circadian conditions; also EEG slow-wave activity, cortisol, GH
result Plasma DSIP-LI significantly decreased at wakefulness-to-sleep transition in both evening (2300h) and morning recovery sleep (0500h); no sleep-stage specificity found.
Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.
Preclinical / mechanistic research
tested rat · [The hypnogenic effects of delta sleep-inducing peptide (DSIP) analogs: a comparative study in rabbits and rats].
result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.
Preclinical / mechanistic research
tested rat · [Delta sleep-inducing peptide and its analogues alleviate the severity of metaphit-induced audiogenic seizures in rats].
result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.
Preclinical / mechanistic research
tested mouse · [Effect of delta-sleep inducing peptide on free-radical processes in the brain and liver of mice during various light regimens].
result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.
Preclinical / mechanistic research
tested mouse · [Shift in the content of immune cytokines in heart of mice under acoustic stress conditions and delta-sleep inducing peptide application].
result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.
Preclinical / mechanistic research
tested mouse · [Effect of delta-sleep inducing peptide preparation Deltaran on longevity, physiological functions, and carcinogenesis in mice].
result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.
Preclinical / mechanistic research
tested rat · [Changes in duodenal lymphoid structures in rats with various behavioral activity, caused by delta sleep-inducing peptide and following acute emotional stress].
result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.
Preclinical / mechanistic research
tested rat · [Effect of delta-sleep inducing peptide on the functional activity of some organs and tissues of rats during physiological aging].
result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.
Preclinical / mechanistic research
tested rat · [Comparison of the effects of DSIP and SP 1-11 on stress-induced chronic sleep disorders in rats].
result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.
Preclinical / mechanistic research
tested rat · [Effects of the δ-sleep inducing peptide on neuronal activity in the dorsal hippocampus of rats with different behavior in the open field after stimulation of the positive and negative emotionalistic structures of the brain].
result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.
Preclinical / mechanistic research
tested rat · [Influence of delta-sleep inducing peptide on the state of lysosomal membranes and intensity of lysosomal proteolysis in different rat tissues during physiological aging of the organism].
result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.
Preclinical / mechanistic research
tested rat · [Influence of delta-sleep peptide on the enzymes activity of mitochondrial electron transport chain in various rat tissues during aging of the organism].
result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.
Preclinical / mechanistic research
tested rat · [THE INFLUENCE OF DELTA SLEEP-INDUCING PEPTIDE ON FUNCTIONAL STATE OF RATS HEPATOCYTES IN FOOT-SHOCK STRESS].
result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.
Preclinical / mechanistic research
tested [Interaction of delta sleep-inducing peptide and its analogues with cellular membranes: a structure-function analysis].
result In-vitro publication captured from PubMed/Europe PMC; assay details require paper-level extraction.
Preclinical / mechanistic research
tested Phosphorylation of delta sleep-inducing peptide (DSIP) by casein kinase II in vitro. (PMID 1815223 · DOI 10.1016/0196-9781(91)90222-b)
result In-vitro publication captured from PubMed/Europe PMC; assay details require paper-level extraction.
Preclinical / mechanistic research
tested [Delta-sleep inducing peptide entrapment and release from polymer hydrogels based on modified polyvinyl alcohol in vitro].
result In-vitro publication captured from PubMed/Europe PMC; assay details require paper-level extraction.